Hyderabad-based drug maker Divi’s Laboratories is expected to report robust year-on-year growth in consolidated net profit when it declares its third quarter earnings on Friday, February 4.
A higher contribution from molnupiravir, an oral anti-viral treatment for COVID-19, and nutraceuticals, or nutritional supplements, as well as strong traction in contract manufacturing are expected to aid the growth.
Revenue is likely to grow 25-30 percent on year and 7-11 percent on a sequential basis in the December quarter.
Profit is forecast to be between Rs 610 and Rs. 700 crore during the quarter. On a sequential basis it is expected to improve between 1 percent and 10 percent.